Analysis of Ghrelin and Asymmetric Dimethylarginine (ADMA) as Endothelial Dysfunction Marker Among Obese Men
Abstract
BACKGROUND: Ghrelin has many biological activities such as regulating energy homeostasis and recent studies have shown its effects in the cardiovascular system. Ghrelin concentration decreases in obese man that indicates relatioship between ghrelin and energy homeostasis. Ghrelin also improves endothelial function by increasing the bioavaibility of nitric oxide (NO). The bioavaibility of NO is also influenced by ADMA. ADMA is an endogenous competitive inhibitor of endothelial nitric oxide synthase (eNOS), which is significantly elevated during endothelial dysfuction. This study aimed to evaluate the relationship of ADMA and ghrelin with central obesity based on waist circumference and to evaluate the relationship of total ghrelin and ADMA in centrally obese men.
METHODS: Total ghrelin and ADMA were measured in 20 non-obese men (waist circumference (WC) 78.85±4.40 cm) and 60 centrally obese men (WC 97.54±5.94 cm). Anthropometric measurements (height, weight, BM, waist circumference and blood pressure) were also recorded. Statistic were carried out by the Spearman and Pearson bivariate correlation analysis and independent sample T test.
RESULTS: ADMA concentrations were significantly higher in centrally obese men than in normal weight controls (p-value <0.05), whereas total ghrelin concentrations were not significantly lower in centrally obese men than in normal weight controls (p-value >0.05). Ghrelin total concentrations were significantly lower in centrally obese men with metabolic syndrome than in normal weight controls (p-value <0.05). No significant correlation existed between total ghrelin and ADMA.
CONCLUSIONS: No correlation existed between ADMA and total ghrelin. The pathway of ghrelin in altering vascular function may not involve ADMA.
KEYWORDS: ghrelin, ADMA, endothelial dysfunction, obese
Full Text:
PDFReferences
Stengel A, Taché Y. Ghrelin – A pleiotropic hormone secreted from endocrine X/A-like cells of the stomach. Front Neurosci. 2012; 6: 24, CrossRef.
Tesauro M, Schinzari F, Caramanti M, Lauro R, Cardillo C. Metabolic and cardiovascular effects of ghrelin. Int J Pept. 2010; 2010: 1-7, CrossRef.
Yin X, Li Y, Xu G, An W, Zhang W. Ghrelin fluctuation, what determines its production? Acta Biochim Biophys Sin. 2009; 41: 188-97, CrossRef.
Pacifico L, Poggiogalle E, Costantino F, Anania C, Ferraro F, Chiarelli F, et al. Acylated and nonacylated ghrelin levels and their associations with insulin resistance in obese and normal weight children with metabolic syndrome. Eur J Endocrinol. 2009; 161: 861-70, CrossRef.
Xu X, Jhun BS, Ha CH, Jin ZG. Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology. 2008; 149: 4183-92, CrossRef.
Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010; 6: 82-90, CrossRef.
Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiol Rev. 2005; 85: 1131-58, CrossRef.
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707-9, CrossRef.
Varela L, Vázquez MJ, Cordido F, Nogueiras R, Vidal-Puig A, Diéguez C, et al. Ghrelin and lipid metabolism: key partners in energy balance. J. Mol. Endocrinol. 2011; 46: R43-63, CrossRef.
Pulkkinen L, Ukkola O, Kolehmainen M, Uusitupa M. Ghrelin in diabetes and metabolic syndrome. Int J Pept. 2010; 2010: 1-11, CrossRef.
Zhang G, Yin X, Qi Y, Pendyala L, Chen J, Hou D, et al. Ghrelin and cardiovascular diseases. Curr Cardiol Rev. 2010; 6: 62-70, CrossRef.
Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the Community. Circulation. 2009; 119: 1592-600, CrossRef.
Koc F, Tokac M, Erdem S, Kaya C, Unlu A, Karabag T, et al. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit. 2010 ; 16: CR536-9, PMID.
Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem. 2010; 56: 111-20, CrossRef.
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99: 3092-5, CrossRef.
Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007; 293: H3227-45, CrossRef.
DOI: https://doi.org/10.18585/inabj.v4i2.167
Copyright (c) 2012 The Prodia Education and Research Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute